Congenital cytomegalovirus infection despite valaciclovir secondary prevention: should we fear antiviral resistance?

Scohy, Anaïs;Gillemot, Sarah;Dirix, Brecht;Bernard, Pierre;Kabamba-Mukadi, Benoît;et.al.
(2024) European Journal of Obstetrics & Gynecology and Reproductive Biology — Vol. 303, p. 367-368 (2024)

Files

2024_Scohy_Eur_J_Obstet_Gynecol_Reprod_Biol_Ab.pdf
  • Open Access
  • Adobe PDF
  • 82.33 KB
Download
2024_Scohy_Eur_J_Obstet_Gynecol_Reprod_Biol.pdf
  • Restricted Access
  • Adobe PDF
  • 330.02 KB
Request a copy

Details

Authors
Show more
Abstract
TO THE EDITOR, Congenital cytomegalovirus (CMV) is a major cause of permanent hearing loss and neurological impairment in children. If vertical transmission rate increases with gestational age at maternal CMV primary infection, the risk of severe fetal impairment is greatest when maternal infection occurs periconceptionally or during the first trimester of pregnancy. Valganciclovir therapy is recommended to treat congenitally infected neonates with significant CMV-related symptoms at birth. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Scohy, A., Gillemot, S., Dirix, B., Bernard, P., Andrei, G., Snoeck, R., & Kabamba-Mukadi, B. (2024). Congenital cytomegalovirus infection despite valaciclovir secondary prevention: should we fear antiviral resistance? European Journal of Obstetrics & Gynecology and Reproductive Biology, 303, 367-368. https://doi.org/10.1016/j.ejogrb.2024.10.002 (Original work published 2024)